Research Article

BAR Score Performance in Predicting Survival after Living Donor Liver Transplantation: A Single-Center Retrospective Study

Talaat Zakareya, 1 Mohammad Taha, 2 Hassan Elzohry, 1 Ehab Darwiesh, 3 Reda Aglan, 1 Mostafa Elhelbawy, 1 Hazem Zakaria, 2 Mohamed Deif, 4 and Mohamed Abbasy 1

1Hepatology and Gastroenterology Department, National Liver Institute, Menoufia University, Shebeen El-Kom, Egypt
2Hepatopancreatobiliary and Liver Transplant Surgery Department, National Liver Institute, Menoufia University, Shebeen El-Kom, Egypt
3Tropical Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
4Radiology Department, National Liver Institute, Menoufia University, Shebeen El-Kom, Egypt

Correspondence should be addressed to Talaat Zakareya; talaatzakareya@gmail.com

Received 10 November 2021; Revised 18 January 2022; Accepted 28 January 2022; Published 18 February 2022

Academic Editor: Kevork M. Peltekian

Copyright © 2022 Talaat Zakareya et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background/Objectives. Studying the predictors of survival after liver transplantation is essential to optimize the outcome. The balance of risk (BAR) score is a predictive model which incorporates six recipient and donor factors. It showed superiority over other predictive models.

Methods. 146 adult liver transplant recipients were included. Univariate and multivariate analyses were used to determine the independent predictors of survival at 3 months, 1 year, and 5 years. The receiver operating characteristic (ROC) curve for the BAR score was plotted, and the area under the ROC curve (AUROC) was calculated. Kaplan–Meier curve and log-rank test were used to compare survival above and below the best cutoff values.

Results. The mean age was 52.45 ± 8.54 years, and 59.6% were males. The survival rates were 89, 78.8, and 72% at 3 months, 1 year, and 5 years, respectively. The BAR score demonstrated a clinically significant value in the prediction of 3-month (AUROC = 0.89), 1-year (AUROC = 0.76), and 5-year survival (AUROC = 0.71). Among the investigated factors associated with survival, BAR score <10 points was the only independent predictor of 3-month (OR 7.34, p < 0.0001), 1-year (OR 3.37, p = 0.001), and 5-year survival (OR 2.83, p = 0.044).

Conclusions. BAR is a simple and easily applicable scoring system that could significantly predict short- and long-term survival after LDLT. A large multicenter study is warranted to validate our results in the Egyptian population.

1. Introduction

Liver transplantation provides a curative treatment for most end-stage liver diseases. Given the increasing demand for liver transplantation, deceased organs are not sufficient enough to meet this increasing demand. Living donor liver transplantation (LDLT) provides an alternative to overcome this organ shortage [1].

Historically, the first liver transplantation in Egypt was performed in 1991 at the National Liver Institute, Menoufia University [2]. Since then, the liver transplantation program has expanded gradually over the past years. Currently, we have around 300 transplants performed at 13 centers across the country each year. For religious, cultural, and traditional beliefs, only LDLT is legalized by Egyptian law whereas deceased donor liver transplantation (DDLT) is prohibited [3]. Complications of hepatitis C virus (HCV) infection represent the leading indication for liver transplantation in Egypt. Several factors affect survival, including recipient, donor, surgical, and perioperative factors [4].

A scoring system that could precisely predict survival after LDLT is required to optimize the outcome. The model for end-stage liver disease (MELD) is a predictive model that was first used in 2000 to predict the survival of cirrhotic
patients after transjugular intrahepatic portosystemic shunt operation [5]. Because of its yield in predicting short-term mortality in cirrhosis, it has been implemented in the United States and most western countries to prioritise liver transplant candidates on the waiting list since 2002. [6, 7].

In recent decades, some predictive models based on both donor and recipient data have been proposed to improve the ability to predict survival after liver transplantation. Rana et al. developed the Survival Outcomes Following Liver Transplantation (SOFT) score in 2008 [8]. The donor age-MELD (D-MELD) score was developed in 2009 as a product of incorporation of the recipient MELD at the time of transplantation and the donor age [9]. The balance of risk (BAR) score was developed by Dutkowski et al. in 2011 [10]. It was developed using the strongest six predictors of post-liver transplant survival derived from the data of 37255 patients in the UNOS (United Network for Organ Sharing) database: donor age (years), recipient age (years), cold ischemia time (hours), retransplantation (yes/no), life support (yes/no), and the MELD score at the time of liver transplant (true value without exception points). BAR score ranges from 0 to 27 points. The MELD score represents the greatest weight variable in the BAR score (0–14 points), followed by retransplantation (0 or 4 points), recipient age (0–3 points), life support (0 or 3 points), cold ischemia time (0–2 points), and donor age (0 or 1 point) [10].

Several studies have confirmed the superiority of BAR over other predictive systems such as donor risk index (DRI), MELD, D-MELD, and SOFT scores [11–15].

The BAR score is not used in nearly all liver transplantation centers in Egypt. This is because the BAR score was primarily developed and validated in Western countries, and there are no published data from Egypt to confirm its utility and validate its use in our population.

The goal of the present study is to evaluate the performance of the BAR score in the prediction of short- and long-term survival after LDLT in the Egyptian population.

2. Materials and Methods

2.1. Study Population. A retrospective observational cohort study was conducted on patients who underwent LDLT for different varieties of liver diseases at the liver transplantation center, National Liver Institute, Menoufa, Egypt, in the period between January 2008 and December 2016. All adult recipients (≥18 years) were enrolled. Pediatric liver transplants were excluded. Also, files with missing or incomplete data were excluded. The total number of liver transplants was 197. The number of pediatric transplants was 23, and the incomplete medical records were 28. The final eligible patients were 146. Demographic, clinical, laboratory, operative, and survival data (3 months, 1 year, and 5 years) for all eligible patients were collected. The BAR score was calculated online for all eligible patients. This is available at http://www.assessurgery.com/bar-score/bar-scorecalculator.

2.2. Statistical Methods. SPSS version 22.0 for Windows (IBM Corp, Armonk, NY, USA) was used for statistical analyses. Descriptive analysis of quantitative variables was expressed as mean and standard deviation (SD), while qualitative variables were presented as numbers and percentages.

Qualitative data were compared using the χ² test or Fisher’s exact test, where appropriate. A paired t-test or Wilcoxon rank test was used to compare continuous variables, while Mann–Whitney, Kruskal–Wallis, or Friedman tests were used to compare nonparametric data. A receiver operating characteristic (ROC) curve was plotted for the BAR score. The power of the BAR score to predict mortality at 3 months, 1 year, and 5 years was reflected by the area under the ROC curve (AUROC). It is widely accepted that the performance of a given diagnostic/prognostic test is adequate when AUROC is ≥ 0.7 while it is considered limited when AUROC is less than 0.7 [16, 17]. The best cutoff value was chosen using the Youden-J statistic (J = sensitivity + specificity – 1). Significant variables associated with survival in univariate analysis have been subjected to multivariate analysis using the Cox regression model. The Kaplan–Meier curve was used for survival analysis at the estimated time points (3 months, 1 year, and 5 years). The log-rank test was used to compare the survival of the groups below and above the chosen BAR cutoff value. The six variables contained in the BAR score were not included in the analysis. Graphical illustrations were created using the SPSS software. All analyses were considered statistically significant when the p value was less than 0.05.

3. Results

The mean age was 52.45 ± 8.54 years. Of those, 87 (59.6%) were males and 59 (40.4%) were females. The main underlying etiology of chronic liver disease was hepatitis C (85.6%). The rest of the patients’ demographic, clinical, laboratory, and operative characteristics are shown in Table 1. The survival rates were 89, 78.8, and 72% at 3 months, 1 year, and 5 years, respectively.

3.1. Three-Month Survival Analysis. Figure 1 represents the ROC curve analysis of the BAR score in predicting 3-month survival. The AUROC was 0.89 (95% CI 0.77–1.0, p < 0.001). Globally, an AUROC between 0.8 and 0.9 indicates an excellent prognostic yield. In view of this fact, the BAR score seems to be an accurate tool in predicting 3-month survival among our patients. The best cutoff value, as indicated by the Youden-J statistic, was 10, with a sensitivity of 87% and a specificity of 78%.

In the univariate analysis, the significant variables associated with higher 3-month survival were a BAR score of less than 10 points (p < 0.001), an operative time of less than 12 hours (p = 0.001), an intraoperative transfusion of less than 6 blood units (p = 0.040), and an ICU stay of less than 10 days (p = 0.046). In the multivariate analysis, the significant independent predictors of 3-month survival were only a BAR score of less than 10 points (OR 7.34, 95% CI 2.06–26.23, p < 0.0001) and a total operative time of less than 12 hours (OR 6.35, 95% CI 2.28–17.68, p = 0.002).
Table 1: Demographic, clinical, laboratory, operative, and survival data.

| Category                          | Mean ± SD, n (%) |
|-----------------------------------|-----------------|
| **Demographics**                  |                 |
| Age (years)                       | 52.45 ± 8.54    |
| Sex                               |                 |
| Males                             | 87 (59.6)       |
| Females                           | 59 (40.4)       |
| **Etiology of liver disease**     |                 |
| HCV                               | 125 (85.6)      |
| HBV                               | 6 (4.1)         |
| Combined HCV and HBV              | 3 (2)           |
| NAFLD                             | 5 (3.4)         |
| AIH                               | 3 (2)           |
| Others                            | 4 (2.7)         |
| **Clinical data**                 |                 |
| BMI (kg/m²)                       | 25.47 ± 3.18    |
| Preexisting DM                    | 31 (21.2)       |
| Preexisting HT                    | 9 (6.2)         |
| Life support                      | 20 (13.7)       |
| ICU stay                          | 9.79 ± 3.40     |
| Total hospital stay               | 24.79 ± 5.65    |
| HCC                               | 37 (25.3)       |
| **Laboratory data and scores**    |                 |
| Albumin (gm/dL)                   | 2.58 ± 0.78     |
| Bilirubin (mg/dL)                 | 3.67 ± 5.51     |
| INR                               | 1.40 ± 0.30     |
| Creatinine (mg/dL)                | 0.98 ± 0.26     |
| AST (IU/L)                        | 66.37 ± 17.87   |
| ALT (IU/L)                        | 40.73 ± 10.79   |
| Hb (gm/dL)                        | 11.06 ± 1.13    |
| WBC (x10³/mm³)                    | 5.00 ± 1.45     |
| Platelets (x10³/mm³)              | 172.87 ± 127.85 |
| MELD score                        | 14.45 ± 5.0     |
| BAR score                         | 7.58 ± 3.83     |
| Donor age (years)                 | 26.45 ± 6.06    |
| **Operative data**                |                 |
| Graft weight (gm)                 | 870.0 ± 15.0    |
| GRWR                              | 1.05 ± 0.15     |
| CIT (minutes)                     | 61.81 ± 25.49   |
| WIT (minutes)                     | 53.01 ± 16.20   |
| TOT (hours)                       | 13.88 ± 3.00    |
| Blood transfusion (units)         | 5.17 ± 4.64     |
| **Survival data**                 |                 |
| Three-month survival              | 130 (89)        |
| One-year survival                 | 115 (78.8)      |
| Five-year survival                | 105 (72)        |

BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Hb, hemoglobin; WBC, white blood count; HCV, hepatitis C virus; INR, international normalized ratio.

(Table 2). The Kaplan–Meier curve and the log-rank test (Figure 2) show a significantly higher 3-month survival in the group of patients with a BAR score of less than 10 points as compared with patients with a BAR score of ≥10 points (93.5% versus 65.2%, χ² = 12.5, p < 0.0001).

3.2. One-Year Survival Analysis. As shown in Figure 3, the AUROC for predicting 1-year survival was 0.76 (95% CI 0.64–0.87, p < 0.001). An AUROC of ≥0.7 indicates a clinically useful prognostic test. So, the BAR score has adequate accuracy in predicting 1-year survival in our patients.

3.3. Five-Year Survival Analysis. Figure 5 represents the ROC of the BAR score in predicting 5-year survival. The AUROC was 0.79 (95% CI 0.62–0.81, p < 0.001). This indicates that the BAR score is a statistically significant model with adequate accuracy in predicting 5-year survival in our population. The selected best cutoff value was 10, with a sensitivity of 56% and a specificity of 77%.

In the univariate analysis, the variables associated with a significantly higher 5-year survival were a BAR score of less than 10 points (p = 0.002) and a total operative time of less than 12 hours (p = 0.009). In multivariate analysis, the only significant independent predictor of 5-year survival was a BAR score of less than 10 points (OR 2.83, 95% CI 1.40–5.70, p = 0.044) (Table 2).
Table 2: Univariate and multivariate analysis of variables associated with survival after LDLT.

| Variables          | Survival 3-month analysis | 1-year survival analysis | 5-year survival analysis |
|-------------------|---------------------------|--------------------------|-------------------------|
|                   | Yes/no 130/16             | Univariate analysis      | Cox regression model    | Survival Yes/no 115/31 | Univariate analysis | Cox regression model | Survival Yes/no 105/41 | Univariate analysis | Cox regression model |
|                   | p value                   | OR CI (95%) p value      |                         |                         | p value              | OR CI (95%) p value |                         |                         | p value              |                         |
| Sex               |                           |                          |                          |                          |                      |                       |                          |                          |                      |                       |
| Males             | 78/9                      |                           | 0.291                    | 69/19                    | 0.703                | 63/24                  | 0.952                    |                          |                      |                       |
| Females           | 52/7                      |                           |                          | 46/12                    | 0.627                | 42/17                  |                          |                          |                      |                       |
| HCC               |                           |                          |                          |                          |                      | 12/25                  |                          |                          |                      |                       |
| No                | 101/8                     |                           | 0.540                    | 92/17                    | 0.815                | 93/16                  | 0.720                    |                          |                      |                       |
| Yes               | 29/8                      |                           |                          | 23/14                    |                      | 12/25                  |                          |                          |                      |                       |
| WIT < 45 min     | 46/4                      |                           | 0.944                    | 37/9                     | 0.627                | 31/15                  | 0.132                    |                          |                      |                       |
| ≥ 45 min         | 84/12                     |                           |                          | 78/22                    |                      | 74/26                  |                          |                          |                      |                       |
| GRWR 0.8–1       | 68/12                     |                           | 0.888                    | 64/16                    | 0.776                | 60/20                  | 0.773                    |                          |                      |                       |
| > 1.0            | 62/4                      |                           |                          | 51/15                    |                      | 45/21                  |                          |                          |                      |                       |
| TOT < 12 hour    | 82/4                      |                           | 0.001*                   | 75/11                    | 0.008*               | 69/17                  | 0.009*                   | 2.66                    | 1.42–5.0              | 0.056                  |
| ≥ 12 hour        | 48/12                     |                           |                          | 40/20                    |                      | 36/24                  |                          |                          |                      |                       |
| Blood transfusion|                           |                          |                          |                          |                      | 93/28                  | 0.284                    |                          |                      |                       |
| < 6 units        | 116/5                     |                           | 0.040*                   | 102/19                   | 0.559                | 93/28                  | 0.284                    |                          |                      |                       |
| ≥ 6 units        | 14/11                     |                           |                          | 13/12                    |                      | 12/13                  |                          |                          |                      |                       |
| ICU stay < 10    | 74/7                      |                           | 1.31 0.47–3.65 0.601     | 101/19                   | 0.559                | 93/28                  | 0.284                    |                          |                      |                       |
| days             | 56/9                      |                           |                          | 13/12                    |                      | 12/13                  |                          |                          |                      |                       |
| ≥ 10 days        |                           |                          |                          |                          |                      | 60/21                  | 0.349                    |                          |                      |                       |
| Total hospital stay < 1 month | 103/15 | 0.046* | 1.12 0.32–3.98 0.860 | 61/15 | 0.156 | 54/16 | 0.349 | | 45/20 |                       |
| ≥ 1 month        | 27/1                      |                           |                          | 119/10                   | 0.719                | 84/34                  | 0.864                    | 19/7                    | 0.864                |                       |
| BAR score < 10   | 115/8                     |                           | 0.327                    | 27/6                     | 0.719                | 84/34                  | 0.864                    | 19/7                    | 0.864                |                       |
| ≥ 10             | 15/8                      |                           | <0.0001*                 | 14/9                     | 0.001*               | 12/11                  | 0.002*                   | 2.83                    | 1.40–5.7              | 0.044*                |

HCC, hepatocellular carcinoma; WIT, warm ischemia time; GRWR, graft recipient weight ratio; TOT, total operative time; ICU, intensive care unit; BAR, balance of risk; *indicates statistically significant value.
The Kaplan–Meier curve and the log-rank test (Figure 6) show a significantly higher 5-year survival in the group of patients with a BAR score of less than 10 points as compared with patients with a BAR score ≥10 points (75.6% versus 52.2%, \( \chi^2 = 6.81, p = 0.009 \)).
The current study demonstrated that the BAR score is excellent in predicting 3-month survival after liver transplantation.

The AUROC was 0.89 (95% CI 0.77–1.0, \( p < 0.001 \)). In the study by Boecker et al., AUROC was 0.847 (CI 0.761–0.934; \( p < 0.001 \)) for the prediction of 90-day mortality [21]. This robust performance of the BAR score has been confirmed in the study by Conjeevaram et al. where the AUROC was 0.80 (CI 0.73–0.88) [15]. Martínez et al. reported similar results in the analysis of 3-month survival; AUROC was 0.755 (95% CI 0.689–0.812) [25].

On the other hand, other studies failed to confirm reasonable accuracy for the BAR score where AUROC came below 0.7 [12, 13, 18, 26]. In the multivariate analysis, a BAR score of less than 10 points was an independent predictor of post-transplant 3-month survival. The survival rates below and above a BAR score of 10 points were 93.5% and 65.2%, respectively \(( p < 0.0001)\). Boecker et al. [21] reported significantly lower 90-day mortality in patients with a BAR score of less than 14 points (2.3% versus 22.2%, respectively; OR 11.857, CI 4.441–31.657, \( p < 0.001 \)). Similarly, Martínez et al. [25] reported that patients with a BAR score of less than 15 points had a significantly higher 3-month survival (93% versus 67%, respectively; Hazard ratio 0.210, 95% CI 0.078–0.562, \( p = 0.01 \)). Our univariate analysis revealed that the number of blood units transfused during the surgery was a statistically significant predictor of 3-month survival \(( p = 0.04)\). However, this finding could not be confirmed in the multivariate analysis. This came in concordance with what was reported by Martínez et al. [25]. Other authors, on the other hand, found a significant association between the amount of transfused blood and short-term mortality after liver transplantation [13, 27, 28]. Also, the ICU stay was statistically significant in the univariate analysis \(( p = 0.046)\), yet it became insignificant in the multivariate analysis. In the study by Stratigopoulou et al., the mean survival of patients with a prolonged ICU stay was significantly lower than that of those discharged from the ICU within 3 days after transplantation surgery (69.057 months, 95% CI 62.402–75.711 versus 87.943 months, 95% CI 81.162–94.724, log-rank test 14.088, \( p < 0.001 \)) [29].

Our results revealed that the BAR score performed well in predicting 1-year survival (AUROC = 0.76, 95% CI 0.64–0.87, \( p < 0.001 \)). This came in consonance with the findings reported by Martínez et al. (AUROC 0.702, 95% CI 0.634–0.764) [25]. The survival rate was significantly higher in the group of patients with a BAR score of less than 10 as compared with those with a BAR score \( \geq 10 \) (82.1% versus 60.9%, \( p = 0.009 \)). Similar findings were reported by Torteroli et al. [26] where one-year survival for patients with a BAR score \( \leq 9 \) was 73.9% versus 51.6% with a BAR \( > 9 \) \(( p = 0.001)\). Also, Martínez et al. have documented a significantly higher one-year survival in patients with a BAR score of less than 15 points than those with a BAR \( \geq 15 \) points (88% versus 59%, \( p < 0.01 \)) [25].

A total operative time of less than 12 hours was found to independently predict 3-month and 1-year post-transplant survival. This is matched with the findings of Stratigopoulou et al. who reported that prolonged duration of transplant

4. Discussion

Studying the predictors of survival after liver transplantation is essential for rationalising the use of resources and avoiding futile transplants. The ideal predictive model should match recipient, donor, and operative factors. In addition, it has to be simple and easy to apply. Several models have emerged with variable usefulness and limitations in clinical practice [15, 18–21]. The SOFT score is complex and not easily applicable as it includes 18 donor and recipient factors [8]. DRI has basically evolved to evaluate graft quality in cadaveric transplantation [9]. Although the MELD score accurately predicts waiting list mortality, its value in predicting post-transplant survival is limited [7, 22, 23]. When developed, the main target of D-MELD was to make a good donor-recipient match in the setting of LDLT. Its basic limitation in LDLT is the negligence of other fundamental operative and perioperative factors that undoubtedly affect the survival outcome. Furthermore, Egyptian law limited the donation age to between 21 and 45 years. In real life, more than 80% of our donors were aged between 21 and 30 years. This could reduce the weight of the age factor in the D-MELD score [3]. The BAR score fulfils most of the proposed criteria of the ideal predictive model, and its utility has been confirmed in the prediction of post-liver transplantation survival outcomes [11–15, 24].

To our knowledge, this is the first study to evaluate the value of the BAR score in predicting survival after liver transplantation in the Egyptian population.
surgery is significantly associated with postoperative complications, prolonged stay in the ICU, and hence increased short-term mortality and reduced overall survival [29].

In continuity of its role in predicting 3-month and 1-year survival, the BAR score showed an adequate accuracy in predicting 5-year survival where AUROC was 0.71 (95% CI 0.62–0.81, \( p < 0.001 \)). This contradicted the findings of Martinez et al., who found that the clinically useful threshold for AUROC could not be reached (AUROC = 0.61) [25]. Likewise, de Boer et al. reported a limited value of the BAR score in predicting post-transplant 5-year survival (c-statistic = 0.56) [20].

In the current study, the cumulative 5-year survival was significantly higher in patients with a BAR score of less than 10 points as compared with those with a BAR score \( \geq 10 \) points (75.6% versus 52.2%, \( p = 0.009 \)). This is concordant to what was reported by Boecker et al. where the five-year survival rate was 76% for BAR \( \leq 14 \) versus 69% for BAR > 14 (\( p = 0.042 \)) [21].

Notably, the BAR score cutoff values were variable among different studies. The selected cutoff value in our cohort was 10 points. The cutoff value used in the current study (10 points) was quite similar to the cutoff value used by Torterolli et al. (9 points). This value, on the other hand, is lower than the cutoffs used by other authors. For example, Boecker et al. used 14 points, Martinez et al. used 15 points, and Dutkowski et al. used 18 points as the best cutoff values [10, 21, 25]. This difference could be explained by the variability in the sample size and the relatively younger donors (26.45 ± 6.06 years) in our cohort. In addition, the mean MELD score, which is a highly weighted component of the BAR score, was lower in the present study as compared with other studies. Furthermore, none of our patients received more than one transplant. For these reasons, the BAR score values in the present study seem to be relatively lower than in other studies.

It has to be noted that using a high cutoff value would be beneficial in deciding the futility of transplantation as reported by Dutkowski et al., who considered a BAR score of \( \geq 18 \) as a critical cutoff point beyond which liver transplantation would be futile where the probability of survival was significantly reduced. Using a lower cutoff value, on the other hand, would maximise the survival benefit while excluding many candidates from receiving a liver transplant. For example, if a BAR score cutoff value of less than 14 points is used to decide futility, patients with a MELD score of \( >35 \) will have a BAR of \( \geq 14 \), which means that they will be excluded from transplant. Furthermore, using a BAR score of less than 10 points will exclude patients with a MELD score of 26–35 (BAR of 10) from transplantation, except if their ages are \( \leq 40 \) years, their donor age is \(<40 \) years, they have no previous transplant, they do not need pre-transplant life support measures, and the cold ischemic time is \( \leq 6 \) h. This conflict indicates that the lower cutoff values that achieve a higher survival outcome should not be necessarily adopted to decide candidacy.

The main shortcomings of the current study are the relatively small sample size and its retrospective and single-center nature.

5. Conclusions

Finally, we can conclude that the BAR score is a reliable simple scoring system that could accurately predict survival after LDLT. A BAR score of less than 10 points independently predicts post-liver transplantation short- and long-term survival in the Egyptian population. A large-scale multicenter prospective study is warranted to validate our results.

Abbreviations

BAR: Balance of risk  
DDLT: Deceased donor liver transplantation  
LDLT: Living donor liver transplantation  
ROC: Receiver operating characteristic curve  
AUROC: Area under the receiver operating characteristic curve  
OR: Odds ratio  
BMI: Body mass index  
MELD: Model for end-stage liver disease  
D-MELD: Donor age-MELD score  
UNOS: United Network for Organ Sharing  
DRI: Donor risk index  
SOFT: Survival outcomes following liver transplantation  
CI: Confidence interval  
ALT: Alanine aminotransferase  
AST: Aspartate aminotransferase  
Hb: Hemoglobin  
WBC: White blood count  
HCV: Hepatitis C virus  
INR: International normalized ratio  
HCC: Hepatocellular carcinoma  
WIT: Warm ischemia time  
GRWR: Graft recipient weight ratio  
ICU: Intensive care unit

Data Availability

The data used to support the findings of this study can be acquired from the corresponding author upon request.

Ethical Approval

The protocol of the present study complied with the international ethical principles of the Declaration of Helsinki (1975) and has been approved by local Institutional Review Board of the National Liver Institute, Menoufia University, Egypt.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors sincerely acknowledge all individuals working at the liver transplant center, National Liver Institute, Menoufia, Egypt, for their kind help and support.
References

[1] M. I. Prince and M. Hudson, "Liver transplantation for chronic liver disease: advances and controversies in an era of organ shortages," *Postgraduate Medical Journal*, vol. 78, no. 917, pp. 135–141, 2002.

[2] H. Khalaf, I. Marwan, M. Al-Sebayel et al., "Status of liver transplantation in the Arab world," *Transplantation*, vol. 97, no. 7, pp. 722–724, 2014.

[3] K. E. Amer and I. Marwan, "Living donor liver transplantation in Egypt," *Hepatobilary Surgery and Nutrition*, vol. 5, no. 2, pp. 98–106, 2016.

[4] S. Elkholy, S. Mogawer, A. Hosny et al., "Predictors of mortality in living donor liver transplantation," *Transplantation Proceedings*, vol. 49, no. 6, pp. 1376–1382, 2017.

[5] M. Malinchoc, P. S. Kamath, F. D. Gordon, C. J. Peine, J. Rank, and P. C. J. ter Borg, "A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts," *Hepatology*, vol. 31, no. 4, pp. 864–871, 2000.

[6] R. Wiesner, S. V. McDiarmid, P. S. Kamath et al., "MELD and PELD: application of survival models to liver allocation," *Liver Transplantation*, vol. 7, no. 7, pp. 567–580, 2001.

[7] R. Wiesner, E. Edwards, R. Freeman et al., "Model for end-stage liver disease (MELD) and allocation of donor livers," *Gastroenterology*, vol. 124, no. 1, pp. 91–96, 2003.

[8] A. Rana, M. A. Hardy, K. J. Halazun et al., "Survival outcomes following liver transplantation (SOFT) score: a novel method to predict patient survival following liver transplantation," *American Journal of Transplantation*, vol. 8, no. 12, pp. 2537–2546, 2008.

[9] J. B. Haldorson, R. Bakhthavatsalam, O. Fix, J. D. Reyes, and J. D. Perkins, "D-MELD, a simple predictor of post liver transplant mortality for optimization of donor/recipient matching," *American Journal of Transplantation*, vol. 9, no. 2, pp. 318–326, 2009.

[10] P. Dutkowski, A. Schlegel, K. Slankamenac et al., "Re there better guidelines for allocation in liver transplantation? A novel score targeting justice and utility in the model for end-stage liver disease era," *Annals of Surgery*, vol. 254, no. 5, pp. 745–754, 2011.

[11] I. Jochmans, D. Monbaliu, and J. Pirenne, "The balance of risk score for allocation in liver transplantation," *Annals of Surgery*, vol. 259, no. 2, p. e34, 2014.

[12] C.-M. Lo, "Use of BAR score as predictor of short and long-term survival of liver transplantation patients," *Hepatology International*, vol. 9, no. 1, pp. 3–4, 2015.

[13] I. D. de Campos Junior, R. S. B. Stucchi, E. Y. Udo, and I. d. P. S. F. Boin, "Application of the BAR score as a predictor of short- and long-term survival in liver transplantation patients," *Hepatology International*, vol. 9, no. 1, pp. 113–119, 2015.

[14] F. Åberg, A. Nordin, H. Mäkisalo, and H. Isoniemi, "Who is too healthy and who is too sick for liver transplantation: external validation of prognostic scores and survival-benefit estimation," *Scandinavian Journal of Gastroenterology*, vol. 50, no. 9, pp. 1144–1151, 2015.

[15] P. K. Conjeevaram Selvakumar, B. Maksimak, I. Hanouneh, D. H. Youssef, R. Lopez, and N. Alkhouri, "Survival outcomes scores (SOFT, BAR, and Pedi-SOFT) are accurate in predicting post-liver transplant survival in adolescents," *Pediatric Transplantation*, vol. 20, no. 6, pp. 807–812, 2016.

[16] J. A. Hanley and B. J. McNeill, "The meaning and use of the area under a receiver operating characteristic (ROC) curve," *Radiology*, vol. 143, no. 1, pp. 29–36, 1982.

[17] M. Jacob, J. D. Lewsey, C. Sharpn, A. Gimson, M. Rela, and J. H. P. van der Meulen, "Systematic review and validation of prognostic models in liver transplantation," *Liver Transplantation*, vol. 11, no. 7, pp. 814–825, 2005.

[18] H. Schrem, A.-L. Platsakis, A. Kaltenborn et al., "Value and limitations of the BAR-score for donor allocation in liver transplantation," *Langenbeck’s Archives of Surgery*, vol. 399, no. 8, pp. 1011–1019, 2014.

[19] Y. Ma, Q. Wang, J. Yang, and L. Yan, "Comparison of different scoring systems based on both donor and recipient characteristics for predicting outcome after living donor liver transplantation," *PLoS One*, vol. 10, no. 9, Article ID e0136604, 2015.

[20] J. D. de Boer, H. Putter, J. J. Blok, I. P. J. Alwayn, B. van Hook, and A. E. Braat, "Predictive capacity of risk models in liver transplantation," *Transplantation Direct*, vol. 5, no. 6, Article ID e457, 2019.

[21] J. Boecker, Z. Czigany, J. Bednarsch et al., "Potential value and limitations of different clinical scoring systems in the assessment of short- and long-term outcome following orthotopic liver transplantation," *PLoS One*, vol. 14, no. 3, Article ID e0214221, 2019.

[22] P. Kamath, R. H. Wiesner, M. Malinchoc et al., "A model to predict survival in patients with end-stage liver disease," *Hepatology*, vol. 33, no. 2, pp. 464–470, 2001.

[23] K. B. Klein, T. D. Stafinski, and D. Menon, "Predicting survival after liver transplantation based on pre-transplant MELD score: a systematic review of the literature," *PLoS One*, vol. 8, no. 12, Article ID e80661, 2013.

[24] P. Dutkowski, A. Schlegel, K. Slankamenac et al., "The use of fatty liver grafts in modern allocation systems: risk assessment by the balance of risk (BAR) score," *Annals of Surgery*, vol. 256, no. 5, pp. 861–869, 2012.

[25] J. A. Martinez, S. Pacheco, J. P. Bachler et al., "Accuracy of the BAR score in the prediction of survival after liver Transplantation," *Annals of Hepatology*, vol. 18, no. 2, pp. 386–392, 2019.

[26] F. Tortorollo, R. K. Watanabe, F. I. Tabushi et al., "BAR, SOFT and DRI post-hepatic transplantation: what is the best for survival analysis?" *ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)*, vol. 34, no. 1, Article ID e1576, 2021.

[27] E. Ramos, A. Dalmau, A. Sabate et al., "Intraoperative red blood cell transfusion in liver transplantation: influence on patient outcome, prediction of requirements, and measures to reduce them," *Liver Transplantation*, vol. 9, no. 12, pp. 1320–1327, 2003.

[28] I. F. S. F. Boin, M. I. Leonardi, A. C. M. Luzo, A. R. Cardoso, C. A. Caruy, and L. S. Leonardi, "Intraoperative massive transfusion decreases survival after liver transplantation," *Transplantation Proceedings*, vol. 40, no. 3, pp. 789–791, 2008.

[29] P. Stratigopoulou, A. Paul, D. P. Hoyer, S. Kykalos, and D. P. Hoyer, "Comparison of different scoring systems based on both donor and recipient characteristics for predicting outcome after living donor liver transplantation," *PLoS One*, vol. 12, no. 3, Article ID e0174173, 2017.